The topic of losing weight with Ozempic often carries an undertone of criticism, with many quick to label it as the "easy way out." But it is not the easy way out.
YOUR comment is why 65% of Americans are fat and 100 mil have FATTY Liver; 96 mil have Metabolic Syndrome and 50 mil have diabetes and all of them are unsexy and unsophisticated too.
Actually, Ozempic acts on the endocannabinoid system to quiet excessive inflammatory cell signalling. Excerpt: "Endocannabinoids and their G-protein coupled receptors (GPCR) are a current research focus in the area of obesity due to the system's role in food intake and glucose and lipid metabolism. Importantly, overweight and obese individuals often have higher circulating levels of the arachidonic acid-derived endocannabinoids anandamide (AEA) and 2-arachidonoyl glycerol (2-AG) and an altered pattern of receptor expression. Consequently, this leads to an increase in orexigenic stimuli, changes in fatty acid synthesis, insulin sensitivity, and glucose utilisation, with preferential energy storage in adipose tissue." https://pubmed.ncbi.nlm.nih.gov/23762050/
Norwegian animal scientists explain how to efficiently quiet excessive cell signaling without having to resort to drugs. " Because arachidonic acid (AA) competes with EPA and DHA as well as with LA, ALA and oleic acid for incorporation in membrane lipids at the same positions, all these fatty acids are important for controlling the AA concentration in membrane lipids, which in turn determines how much AA can be liberated and become available for prostaglandin biosynthesis following phospholipase activation. Thus, the best strategy for dampening prostanoid overproduction in disease situations would be to reduce the intake of AA, or reduce the intake of AA at the same time as the total intake of competing fatty acids (including oleic acid) is enhanced, rather than enhancing intakes of EPA and DHA only. Enhancement of membrane concentrations of EPA and DHA will not be as efficient as a similar decrease in the AA concentration for avoiding prostanoid overproduction. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2875212/
YOUR comment is why 65% of Americans are fat and 100 mil have FATTY Liver; 96 mil have Metabolic Syndrome and 50 mil have diabetes and all of them are unsexy and unsophisticated too.
Actually, Ozempic acts on the endocannabinoid system to quiet excessive inflammatory cell signalling. Excerpt: "Endocannabinoids and their G-protein coupled receptors (GPCR) are a current research focus in the area of obesity due to the system's role in food intake and glucose and lipid metabolism. Importantly, overweight and obese individuals often have higher circulating levels of the arachidonic acid-derived endocannabinoids anandamide (AEA) and 2-arachidonoyl glycerol (2-AG) and an altered pattern of receptor expression. Consequently, this leads to an increase in orexigenic stimuli, changes in fatty acid synthesis, insulin sensitivity, and glucose utilisation, with preferential energy storage in adipose tissue." https://pubmed.ncbi.nlm.nih.gov/23762050/
The problem is too much arachidonic acid in the food supply and not enough of the omega-3s. https://pubmed.ncbi.nlm.nih.gov/33914036/
Norwegian animal scientists explain how to efficiently quiet excessive cell signaling without having to resort to drugs. " Because arachidonic acid (AA) competes with EPA and DHA as well as with LA, ALA and oleic acid for incorporation in membrane lipids at the same positions, all these fatty acids are important for controlling the AA concentration in membrane lipids, which in turn determines how much AA can be liberated and become available for prostaglandin biosynthesis following phospholipase activation. Thus, the best strategy for dampening prostanoid overproduction in disease situations would be to reduce the intake of AA, or reduce the intake of AA at the same time as the total intake of competing fatty acids (including oleic acid) is enhanced, rather than enhancing intakes of EPA and DHA only. Enhancement of membrane concentrations of EPA and DHA will not be as efficient as a similar decrease in the AA concentration for avoiding prostanoid overproduction. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2875212/